[go: up one dir, main page]

ECSP22073580A - Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano - Google Patents

Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano

Info

Publication number
ECSP22073580A
ECSP22073580A ECSENADI202273580A ECDI202273580A ECSP22073580A EC SP22073580 A ECSP22073580 A EC SP22073580A EC SENADI202273580 A ECSENADI202273580 A EC SENADI202273580A EC DI202273580 A ECDI202273580 A EC DI202273580A EC SP22073580 A ECSP22073580 A EC SP22073580A
Authority
EC
Ecuador
Prior art keywords
compound
formula
methods
antibacterial agent
oxazolidinone compound
Prior art date
Application number
ECSENADI202273580A
Other languages
English (en)
Inventor
Brendan Crowley
Lihu Yang
Lanying You
Takao Suzuki
Philippe Nantermet
Xin Yao
Original Assignee
Merck Sharp Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp Dohme Llc filed Critical Merck Sharp Dohme Llc
Publication of ECSP22073580A publication Critical patent/ECSP22073580A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/24—Oxygen atoms attached in position 2 with hydrocarbon radicals, substituted by oxygen atoms, attached to other ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

La presente invención se refiere al compuesto de oxazolidinona de la Fórmula I: (I) y sales farmacéuticamente aceptables del mismo. La presente invención también se refiere a composiciones que contienen el compuesto de la Fórmula I. La invención también proporciona métodos para inhibir el crecimiento de células micobacterianas así como un método para tratar infecciones por micobacterias por Mycobacterium tuberculosis al administrar una cantidad terapéuticamente eficaz de la Fórmula I y/o una sal farmacéuticamente aceptable del mismo, o una composición que comprende tal compuesto y/o sal.
ECSENADI202273580A 2020-03-20 2022-09-19 Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano ECSP22073580A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2020/080359 WO2021184339A1 (en) 2020-03-20 2020-03-20 Oxazolidinone compound and methods of use thereof as an antibacterial agent

Publications (1)

Publication Number Publication Date
ECSP22073580A true ECSP22073580A (es) 2022-11-30

Family

ID=75478174

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202273580A ECSP22073580A (es) 2020-03-20 2022-09-19 Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano

Country Status (21)

Country Link
US (1) US12435077B2 (es)
EP (1) EP4121058A1 (es)
JP (1) JP7241984B2 (es)
KR (1) KR102824010B1 (es)
CN (1) CN115605208A (es)
AR (1) AR121598A1 (es)
AU (1) AU2021239937B2 (es)
BR (1) BR112022018674A2 (es)
CA (1) CA3172304A1 (es)
CL (1) CL2022002511A1 (es)
CO (1) CO2022013595A2 (es)
CR (1) CR20220472A (es)
EC (1) ECSP22073580A (es)
GE (2) GEAP202416059A (es)
IL (1) IL296401A (es)
MX (1) MX2022011431A (es)
NZ (1) NZ792402A (es)
PE (1) PE20230002A1 (es)
PH (1) PH12022552495A1 (es)
TW (1) TWI799814B (es)
WO (2) WO2021184339A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022025918A2 (pt) 2020-06-18 2023-03-14 Akagera Medicines Inc Compostos de oxazolidinona, composições lipossomais que compreendem compostos de oxazolidinona e métodos de uso dos mesmos
CN118317771A (zh) * 2021-11-30 2024-07-09 曼金德公司 用于局部治疗布鲁里溃疡中的溃疡分枝杆菌的制剂和方法
EP4296674A1 (en) 2022-06-20 2023-12-27 Université Toulouse III - Paul Sabatier Innovative molecules decreasing virulence of mycobacterium for the treatment of tuberculosis
EP4568961A1 (en) * 2022-08-10 2025-06-18 Merck Sharp & Dohme LLC Processes for preparing oxazolidinone compounds

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4948801A (en) 1988-07-29 1990-08-14 E. I. Du Pont De Nemours And Company Aminomethyloxooxazolidinyl arylbenzene derivatives useful as antibacterial agents
KR100257418B1 (ko) 1991-11-01 2000-05-15 로렌스 티. 마이젠헬더 치환된 아릴-및 헤테로아릴-페닐옥사졸리디논
SK283420B6 (sk) * 1992-05-08 2003-07-01 Pharmacia & Upjohn Company Antimikrobiálne oxazolidinóny obsahujúce substituované diazínové skupiny
MY115155A (en) 1993-09-09 2003-04-30 Upjohn Co Substituted oxazine and thiazine oxazolidinone antimicrobials.
DE69631347T2 (de) 1995-09-15 2004-10-07 Upjohn Co Aminoaryl oxazolidinone n-oxide
CZ298060B6 (cs) 1996-04-11 2007-06-06 Pharmacia & Upjohn Company Zpusob prípravy oxazolidinonu
US6255304B1 (en) 1997-05-30 2001-07-03 Pharmacia & Upjohn Company Oxazolidinone antibacterial agents having a thiocarbonyl functionality
DE69829846T2 (de) 1997-05-30 2006-02-23 Pharmacia & Upjohn Co. Llc, Kalamazoo Antibakteriell wirksam oxazolidinone mit einer thiocarbonylfunktionalität
NZ508256A (en) 1998-05-18 2003-08-29 Upjohn Co Enhancement of oxazolidinone antibacterial agents activity by using arginine derivatives
JP2000204084A (ja) 1998-11-11 2000-07-25 Hokuriku Seiyaku Co Ltd チオカルバミド酸誘導体
JP2002531455A (ja) 1998-11-27 2002-09-24 ファルマシア・アンド・アップジョン・カンパニー チオカルボニル官能基を有するオキサゾリジノン抗細菌剤
US6297242B1 (en) 1999-08-12 2001-10-02 Ortho-Mcneil Pharmaceutical, Inc. N-substituted amidine and guanidine oxazolidinone antibacterials and methods of use thereof
PL356478A1 (en) * 1999-12-21 2004-06-28 Pharmacia & Upjohn Company Oxazolidinones having a sulfoximine functionality and their use as antimicrobial agents
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
AU5311301A (en) 2000-04-20 2001-11-07 Upjohn Co Use of thioamide oxazolidinones for the treatment of bone resorption and osteoporosis
MXPA02012045A (es) 2000-06-05 2003-10-15 Dong A Pharm Co Ltd Nuevos derivados de oxazolidinona y proceso para su preparacion.
PE20020044A1 (es) 2000-06-16 2002-01-30 Upjohn Co Tiazina oxazolidinona
US6544991B2 (en) 2000-06-30 2003-04-08 Pharmacia & Upjohn Company Compositions and methods for treating bacterial infections
US6696426B2 (en) 2000-08-22 2004-02-24 Pharmacia Corporation Preservative free ophthalmic oxazolidinone antibiotic drug delivery systems
PE20020300A1 (es) 2000-08-22 2002-05-10 Pharmacia Corp Composicion de solucion de un farmaco antibiotico a base de oxazolidinona con mejoramiento de la carga de farmaco
AR031135A1 (es) * 2000-10-10 2003-09-10 Upjohn Co Composiciones de antibiotico topico para el tratamiento de infecciones oculares
ATE321024T1 (de) * 2000-10-17 2006-04-15 Pharmacia & Upjohn Co Llc Verfahren zur herstellung von oxazolidinonverbindungen
CA2441854A1 (en) * 2001-02-05 2002-09-19 Pharmacia & Upjohn Company Composition for rectal delivery of an oxazolidinone antibacterial drug
GB0108764D0 (en) * 2001-04-07 2001-05-30 Astrazeneca Ab Chemical compounds
AU2002255803B2 (en) 2001-04-20 2008-07-03 Pharmacia And Upjohn Company Process to prepare oxazolidinones
US6774231B2 (en) 2001-04-20 2004-08-10 Pharmacia & Upjohn Company Method for the preparation of oxazolidinones
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
EP1406880A1 (en) 2001-07-10 2004-04-14 PHARMACIA & UPJOHN COMPANY Crystalline thiazine oxazolidinones
EP1451164A2 (en) 2001-07-12 2004-09-01 PHARMACIA & UPJOHN COMPANY Amide derivatives having improved solubility
US20030069235A1 (en) 2001-09-14 2003-04-10 J. Greg Slatter Treatment for ocular infections
JP3778425B2 (ja) 2001-10-03 2006-05-24 日立金属株式会社 表示装置に用いられる電子部品用Ａｇ合金膜および表示装置に用いられる電子部品用Ａｇ合金膜形成用スパッタリングターゲット材
BR0307103A (pt) 2002-01-24 2004-12-28 Upjohn Co Dihidrotiazina e dihidrotiopirano oxazolidinovas antimicrobianas
TW200302095A (en) 2002-01-25 2003-08-01 Upjohn Co Oxazolidinone cotherapy
EP1476135A1 (en) 2002-02-22 2004-11-17 Pharmacia Corporation Ophthalmic formulation with gum system
BR0307898A (pt) * 2002-02-22 2004-12-07 Pharmacia Corp Formulações de droga antibiótica oftálmica contendo um composto de ciclodextrina e cloreto de cetil piridìnio
AU2003207340A1 (en) 2002-02-28 2003-09-09 Astrazeneca Ab 3-cyclyl-5-(nitrogen-containing 5-membered ring) methyl-oxazolidinone derivatives and their use as antibacterial agents
WO2003093247A2 (en) 2002-04-30 2003-11-13 Orchid Chemicals & Pharmaceuticals Ltd Antibacterial agents
TW200403240A (en) 2002-06-28 2004-03-01 Upjohn Co Difluorothioacetamides of oxazolidinones as antibacterial agents
DE60304360T2 (de) 2002-08-12 2006-11-16 Pharmacia & Upjohn Co. Llc, Kalamazoo N-aryl-2-oxazolidinone und deren derivate
WO2004026848A1 (en) 2002-09-20 2004-04-01 Lupin Limited Oxazolidinone derivatives, process for their preperation and their use as antimycobacterial agents
JP2004203809A (ja) 2002-12-26 2004-07-22 Meiji Seika Kaisha Ltd 新規ビフェニル誘導体
US20040191326A1 (en) 2003-03-31 2004-09-30 Reo Joseph P. Taste-masking vehicle for coated oxazolidinone particles
ZA200510432B (en) 2003-07-02 2007-03-28 Merck & Co Inc Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof
US20070185132A1 (en) 2003-07-02 2007-08-09 Yasumichi Fukuda Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereo
WO2005005398A2 (en) 2003-07-02 2005-01-20 Merck & Co., Inc. Cyclopropyl group substituted oxazolidinone antibiotics and derivatives thereof
US7047020B2 (en) 2003-07-16 2006-05-16 Qualcomm Inc. Assistance techniques for subscriber units having positioning capabilities
EP1660488A1 (en) 2003-08-25 2006-05-31 Warner-Lambert Company LLC Novel antimicrobial aryloxazolidinone compounds
US7265140B2 (en) 2003-09-23 2007-09-04 Pfizer Inc Acyloxymethylcarbamate prodrugs of oxazolidinones
ES2294494T3 (es) 2004-04-19 2008-04-01 Symed Labs Limited Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados.
WO2005113520A1 (en) * 2004-05-20 2005-12-01 Pharmacia & Upjohn Company Llc Substituted 2,3,5-trifluorphenyl oxazolidinones for use as antibacterial agents
WO2006008754A1 (en) 2004-07-20 2006-01-26 Symed Labs Limited Novel intermediates for linezolid and related compounds
JP2008508271A (ja) 2004-07-28 2008-03-21 リブ−エックス ファーマシューティカルズ，インコーポレイテッド ビアリール複素環式化合物ならびにその化合物を製造および使用する方法
TW200612923A (en) 2004-07-29 2006-05-01 Ferrer Int Oxazolidinone compounds and compositions and methods related thereto
WO2006038100A1 (en) 2004-10-08 2006-04-13 Ranbaxy Laboratories Limited Oxazolidinone derivatives as antimicrobials
WO2006059221A2 (en) * 2004-12-03 2006-06-08 Pharmacia & Upjohn Company Llc Topical hydro-alcoholic formulations of oxazolidinone antibacterial agents
WO2006079896A2 (en) * 2005-01-27 2006-08-03 Pharmacia & Upjohn Company Llc Stable polyol formulations of oxazolidinone antibacterial agents
US20090018123A1 (en) 2005-06-20 2009-01-15 Milind D Sindkhedkar Oxazolidinones Bearing Antimicrobial Activity Composition and Methods of Preparation
EP1745784A1 (en) 2005-06-27 2007-01-24 Ferrer Internacional, S.A. Oxazolidinone derivatives and use thereof as antibiotics
DE102005047558A1 (de) 2005-10-04 2008-02-07 Bayer Healthcare Ag Kombinationstherapie substituierter Oxazolidinone zur Prophylaxe und Behandlung von cerebralen Durchblutungsstörungen
DE102005048824A1 (de) 2005-10-10 2007-04-12 Bayer Healthcare Ag Behandlung und Prophylaxe von Mikroangiopathien
DE102006051625A1 (de) 2006-11-02 2008-05-08 Bayer Materialscience Ag Kombinationstherapie substituierter Oxazolidinone
WO2008070619A1 (en) 2006-12-04 2008-06-12 Auspex Pharmaceuticals, Inc. Deuterated oxazolidinones and their use as antibiotics
WO2008069619A1 (en) 2006-12-08 2008-06-12 Legochem Bioscience Ltd. Novel oxazolidinone derivatives, process for preparing thereof and pharmaceutical composition containing the same
CN101720325B (zh) 2007-08-06 2013-04-24 上海盟科药业有限公司 用于治疗细菌感染的抗菌邻-氟苯基噁唑烷酮
JPWO2009157423A1 (ja) 2008-06-24 2011-12-15 財団法人乙卯研究所 縮合環を有するオキサゾリジノン誘導体
NZ591169A (en) 2008-09-03 2012-12-21 Pfizer Combination therapy for tuberculosis
WO2010084514A2 (en) 2009-01-02 2010-07-29 Neuland Laboratories Ltd. A process for the preparation of (5s)-(n)-[[3-[3-fluoro-4-(4-morpholinyl) phenyl]-2-oxo-5-oxazolidinyl] methyl] acetamide
CN101993448A (zh) 2009-08-24 2011-03-30 上海柯盟医药技术有限公司 可用于治疗传染病的抗分枝杆菌的噁唑烷酮
EP2311457A1 (en) * 2009-10-19 2011-04-20 Forschungszentrum Borstel Pharmaceutical compositions for treating infections with drug resistant mycobacteria
WO2012082992A1 (en) 2010-12-15 2012-06-21 Biovista, Inc. Compositions and methods for cancer treatment
KR101271224B1 (ko) 2011-07-05 2013-06-10 한국과학기술연구원 항균활성을 갖는 신규 이중고리를 포함하는 옥사졸리디논 유도체 및 이의 제조방법
EA037643B1 (ru) 2015-07-17 2021-04-26 Зе Глобал Эллайенс Фо Тб Драг Девелопмент, Инк. Замещенные фенилоксазолидиноны для антимикробной терапии
WO2017066964A1 (en) * 2015-10-22 2017-04-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
WO2017143112A2 (en) 2016-02-17 2017-08-24 The Johns Hopkins University An oxazolidinone for treatment of infections with mycobacterium tuberculosis
ITUA20161708A1 (it) 2016-02-25 2017-08-25 Riccardo Curto Sistema di parcheggio automatizzato
WO2018170664A1 (en) * 2017-03-20 2018-09-27 Merck Sharp & Dohme Corp. Oxazolidinone compounds and methods of use thereof as antibacterial agents
GB201814487D0 (en) 2018-09-06 2018-10-24 Cycle Pharmaceuticals Ltd Cancer
US12365656B2 (en) 2019-01-18 2025-07-22 Merck Sharp & Dohme Llc Oxazolidinone compounds and methods of use thereof as antibacterial agents

Also Published As

Publication number Publication date
BR112022018674A2 (pt) 2022-11-01
CR20220472A (es) 2022-11-14
PE20230002A1 (es) 2023-01-05
US12435077B2 (en) 2025-10-07
PH12022552495A1 (en) 2024-03-25
KR102824010B1 (ko) 2025-06-20
IL296401A (en) 2022-11-01
TW202200573A (zh) 2022-01-01
GEP20247641B (en) 2024-07-10
CO2022013595A2 (es) 2023-02-16
AR121598A1 (es) 2022-06-22
EP4121058A1 (en) 2023-01-25
NZ792402A (en) 2025-09-26
CL2022002511A1 (es) 2023-03-24
JP7241984B2 (ja) 2023-03-17
TWI799814B (zh) 2023-04-21
KR20220156577A (ko) 2022-11-25
WO2021188606A1 (en) 2021-09-23
US20240208958A1 (en) 2024-06-27
GEAP202416059A (en) 2024-02-26
AU2021239937A1 (en) 2022-10-06
CN115605208A (zh) 2023-01-13
CA3172304A1 (en) 2021-09-23
MX2022011431A (es) 2022-10-03
WO2021184339A1 (en) 2021-09-23
AU2021239937B2 (en) 2023-10-26
JP2023507683A (ja) 2023-02-24

Similar Documents

Publication Publication Date Title
ECSP22073580A (es) Compuesto de oxazolidinona y métodos de uso de este como agente antibacteriano
ECSP21080528A (es) Compuestos antivirales que contienen nitrilo
CL2021001042A1 (es) Nuevos compuestos antihelmínticos
UY39780A (es) Composición fungicida que contiene compuestos de oxadiazol
AR112271A1 (es) Composiciones que comprenden un inhibidor de arn polimerasa y ciclodextrina para el tratamiento de infecciones virales
MX385731B (es) Compuestos de biaril-monobactam y métodos de uso de los mismos para el tratamiento de infecciones bacterianas.
PE20201256A1 (es) Compuestos monobactamicos cromanos para el tratamiento de infecciones bacterianas
MX2024002538A (es) Uso de un inhibidor de la ezh2 en la preparacion de farmacos para el tratamiento del linfoma de linfocitos t.
UY39027A (es) Uso de favipiravir en el tratamiento de la infección por coronavirus
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
ECSP21093897A (es) Compuestos y métodos de uso de los mismos como agentes antibacterianos
CO2022008616A2 (es) Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma
BR112021025618A2 (pt) Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto
MX2019003585A (es) Derivados de tetrahidropiridina y su uso como agentes antibacterianos.
BR112017008101A2 (pt) composto, composição farmacêutica, métodos para inibir o dnae bacteriano e para tratar uma infecção, e, uso de um composto.
DOP2025000235A (es) Nuevo compuesto, y una composición farmacéutica para la prevención o el tratamiento del cáncer o tumores que comprende el mismo
MX2024014106A (es) Composiciones para prevenir o tratar la fibrosis pulmonar idiopatica (ipf)
AR121582A1 (es) Composiciones antivirales y métodos de uso
AR130252A1 (es) Inhibidores enzimáticos
CO2023001204A2 (es) Composición oral sólida que comprende compuesto de carbamato y método de preparación para la misma
AR134544A1 (es) Combinaciones farmacéuticas para su uso en el tratamiento de infecciones fúngicas
CL2022001935A1 (es) Compuestos antivirales que contienen nitrilo
AR127582A1 (es) Métodos para el tratamiento del cáncer